MiR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis.

Abstract

In hypoxic conditions, miRNA-210 plays an important role in regulating the expression of hypoxia-inducing factor-1α (HIF-1α) and the differentiation of T helper 17 (Th17) cells, and this may be involved in the development and function of the immune system. This study was to investigate the miR-210 expression levels in peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and its association with the clinical and laboratory features of both diseases. Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect miR-210 expression levels in PBMCs from 35 patients with SLE, 38 patients with RA, and 35 healthy controls. Compared with the healthy controls, the miR-210 expression levels were significantly increased in patients with SLE (P=0.001) and there was increased significantly expression of miR-210 in SLE with pleuritis (Z=-2.345, P=0.019) and anti-SSB/La-positive group (Z=-2.076, P=0.038). However, we have not found the significant correlation between the miR-210 levels and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (r s=0.091, P=0.602). Although, no significant difference between miR-210 levels in RA patients and those in healthy controls was found (Z=-1.226, P=0. 220). There was a significant decreased expression of miR-210 in active RA patients than inactive RA patients (Z=-4.011, P<0.001). The dysregulation of miR-210 levels in SLE and RA patients suggests that miR-210 might play an important role in the pathogenesis of these diseases.